ON-LINE DATA SUPPLEMENT

Benefits of Sequentially Adding Cognitive Behavior Therapy or Antidepressant Medication in Non-remitting Depressed Adults

Boadie W. Dunlop, MD, Devon LoParo, PhD, Becky Kinkead, PhD, Tanja Mletzko-Crowe MA, Steven P. Cole, PhD, Charles B. Nemeroff, MD, PhD, Helen S. Mayberg, MD, W. Edward Craighead, PhD

Supplement Contents:

1. **Table S1.** Antidepressant medication exposure during Phase II Combination by treatment arm
2. **Table S2.** Antidepressant medication maintenance during 18-month long-term follow-up of Phase II completers who entered follow-up phase
3. **Table S3**. Predictors of Phase I or II Remission among completers (n=251)
4. **Figure S1.** CONSORT Diagram for Phase II Combination Treatment in PReDICT Study
5. **Figure S2.** CONSORT Diagram for 18-month Follow-up Phase in PReDICT Study

Table S1. Antidepressant medication exposure during Phase II Combination by treatment arm

	Phase II Combination Treatment Arm				
	CBT+MED		MED+CBT		p
Completers, n	31		66		
Stopped medication prior to Week 24, n (%)	2	(6.5)	1	(1.5)	.19
Days on medication from Phase II baseline to last Phase II visit, mean (SD)	83.7	(16.3)	86.6	(13.0)	.35
Early Terminators, n	6		9		
Stopped medication prior to termination visit, n (%)	0	(0)	0	(0)	--
Days on medication from Phase II baseline to last Phase II visit, mean (SD)	40.8	(21.3)	39.8	(23.7)	.93
All Phase II Patients, n	37		75		
Stopped medication prior to Week 24, n (%)	2	(5.4)	1	(1.3)	.21
Days on medication from Phase II baseline to last Phase II visit, mean (SD)	76.7	(23.5)	81.0	(21.0)	.34

CBT+MED: Cognitive behavior therapy in Phase I, with addition of escitalopram in Phase II

MED+CBT: Escitalopram or duloxetine in Phase I, with addition of cognitive behavior therapy in Phase II

Table S2. Antidepressant medication maintenance during 18-month long-term follow-up of Phase II completers who entered follow-up phase

	Stopped medication prior to last follow-up visit, n (%)	Days on medication from end of Phase II, mean ± SD	Days on medication from Phase II baseline, mean ± SD
CBT+MED (n= 26)	8 (30.8%)	370 ± 218	457 ± 216
MED+CBT (n= 53)	13 (24.5%)	374 ± 189	462 ± 190
p-value	.56	.93	.90
MED+CBT subgroups			
Escitalopram+CBT (n= 35)	9 (25.7%)	389 ± 184	479 ± 186
Duloxetine+CBT (n= 18)	4 (22.2%)	345 ± 199	433 ± 197
p-value	.78	.42	.41

CBT+MED: Cognitive behavior therapy in Phase I, with addition of escitalopram in Phase II

MED+CBT: Escitalopram or duloxetine in Phase I, with addition of cognitive behavior therapy in Phase II

Table S3. Predictors of Phase I or II Remission among completers (n=251)

Variable	Predictor effect		
	Wald X^2	df	p
Severity (HAM-D) at Week 1	6.437	1	0.011*
Chronic episode	0.308	1	0.579
Age	2.839	1	0.092
Anxiety (HAM-A) at Week 1	11.112	1	0.001*
Current Anxiety Disorder	6.859	1	0.009*
Gender	2.437	1	0.119
Race	0.579	3	0.901
Married/cohabitating	1.878	1	0.171
Employed full time	0.111	1	0.739

* $p < .05$

**Figure S1.** CONSORT Diagram for Phase II Combination Treatment in PReDICT Study

Figure S2. CONSORT Diagram for 18-month Follow-up Phase in PReDICT Study